Replies to post #89364 on $heff's $tation of $tocks & $olid DD

[beach_trades]

$SNSS Vosaroxin Phase 3 VALOR Trial Results in September Issue of The Lancet Oncology

- Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

- the prespecified secondary analysis stratified by randomisation factors suggests that the addition of vosaroxin to cytarabine might be of clinical benefit to some patients with relapsed or refractory acute myeloid leukaemia.

http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00201-6/abstract

I like the chart here and worst appears priced in. 1.50 and into the gap is target